Multiple Myeloma News

What ESO-T01 Tells Us About the Next Frontier in Multiple Myeloma - CancerNetwork

What ESO-T01 Tells Us About the Next Frontier in Multiple Myeloma CancerNetwork

Exposure-response analyses for belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma from DREAMM-6 Arm B and DREAMM-7 - Nature

Exposure-response analyses for belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma from DREAMM-6 Arm B and DREAMM-7 Nature

Pancytopenia and Methemoglobinemia in a Patient With Multiple Myeloma Presenting With Syncope and Dyspnoea: A Diagnostic Challenge - Cureus

Pancytopenia and Methemoglobinemia in a Patient With Multiple Myeloma Presenting With Syncope and Dyspnoea: A Diagnostic Challenge Cureus

Dual-Targeting CAR T Achieves sCR in 100% of Older Patients With NDMM - Targeted Oncology

Dual-Targeting CAR T Achieves sCR in 100% of Older Patients With NDMM Targeted Oncology

Bristol Myers Squibb evolves and expands multiple myeloma programme - PMLiVE

Bristol Myers Squibb evolves and expands multiple myeloma programme PMLiVE

Before the Clot Forms: Role of the IMPEDE VTE Score in Multiple Myeloma - Cancer Nursing Today

Before the Clot Forms: Role of the IMPEDE VTE Score in Multiple Myeloma Cancer Nursing Today

Infection Burden High With Myeloma T-Cell Therapies - Medscape

Infection Burden High With Myeloma T-Cell Therapies Medscape

Myeloma Paper of the Day, April 13th, Suggested by Robert Orlowski - Oncodaily

Myeloma Paper of the Day, April 13th, Suggested by Robert Orlowski Oncodaily

Woman Thought She Was Just Tired From Her Hectic Schedule, but Secretly, Her Kidneys Were Failing - Parade

Woman Thought She Was Just Tired From Her Hectic Schedule, but Secretly, Her Kidneys Were Failing Parade

Key Factors Influencing Treatment Selection in Relapsed and Refractory Multiple Myeloma - OncLive

Key Factors Influencing Treatment Selection in Relapsed and Refractory Multiple Myeloma OncLive

Belantamab Combo Shows Promise in Multiple Myeloma - Bioengineer.org

Belantamab Combo Shows Promise in Multiple Myeloma Bioengineer.org

Are multiple myeloma rates higher in Western New York? - Roswell Park Comprehensive Cancer Center

Are multiple myeloma rates higher in Western New York? Roswell Park Comprehensive Cancer Center

Multiple Myeloma: Improved Prognosis With the Latest Treatments - Memorial Sloan Kettering Cancer Center

Multiple Myeloma: Improved Prognosis With the Latest Treatments Memorial Sloan Kettering Cancer Center

New advances are transforming blood cancer care - Loma Linda University

New advances are transforming blood cancer care Loma Linda University

You Have Cancer! Living Decades After Diagnosis - WNEM

You Have Cancer! Living Decades After Diagnosis WNEM

Examining Real-World Approaches for GPRC5D Bispecific in Multiple Myeloma - Targeted Oncology

Examining Real-World Approaches for GPRC5D Bispecific in Multiple Myeloma Targeted Oncology

Role of Bispecific Antibodies in Multiple Myeloma - CancerNetwork

Role of Bispecific Antibodies in Multiple Myeloma CancerNetwork

Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium - Nature

Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium Nature

Enhanced dynamic risk stratification of smoldering multiple myeloma - Nature

Enhanced dynamic risk stratification of smoldering multiple myeloma Nature

In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study - Nature

In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study Nature

CD70/CD27 signaling promotes the pathogenesis of multiple myeloma and represents a promising therapeutic target - Nature

CD70/CD27 signaling promotes the pathogenesis of multiple myeloma and represents a promising therapeutic target Nature

Antibody Therapy Eradicates Traces of Multiple Myeloma in Preliminary Trial - University of Miami

Antibody Therapy Eradicates Traces of Multiple Myeloma in Preliminary Trial University of Miami

“Massive Shift” Prompts ASCO to Update Guideline for Multiple Myeloma - Oncology News Central

“Massive Shift” Prompts ASCO to Update Guideline for Multiple Myeloma Oncology News Central

Belantamab Mafodotin Regimen Shows Activity in Transplant-Ineligible NDMM - CancerNetwork

Belantamab Mafodotin Regimen Shows Activity in Transplant-Ineligible NDMM CancerNetwork

Clinical trial led by UAB researcher supports approval of new, potentially curative treatment for multiple myeloma - The University of Alabama at Birmingham

Clinical trial led by UAB researcher supports approval of new, potentially curative treatment for multiple myeloma The University of Alabama at Birmingham

Diets for MGUS, Smoldering Myeloma, and Multiple Myeloma: Q&A With MSK Cancer and Nutrition Experts - Memorial Sloan Kettering Cancer Center

Diets for MGUS, Smoldering Myeloma, and Multiple Myeloma: Q&A With MSK Cancer and Nutrition Experts Memorial Sloan Kettering Cancer Center